A. E. Chervyakov
A. E. Chervyakov has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Elena V. Stezhkina
Federal State Budgetary Educational Institution of Higher Education “Ryazan State Medical University named after Academician I. P. Pavlov” of the Ministry of Health of the Russian Federation
2 shared publications - Lyudmila V. Korshunova
Federal State Budgetary Educational Institution of Higher Professional “Ryazan State Medical University”, Ministry of Healthcare of the Russian Federation
2 shared publications A. B. Шаханов
Федеральное государственное бюджетное образовательное учреждение высшего образования «Рязанский государственный медицинский университет имени академика И.П.Павлова» Министерства здравоохранения Российской Федерации
1 shared publication- Anton V. Shakhanov
Ryazan State Medical University named after academician I.P. Pavlov
1 shared publication - M. V. Chaplanov
Federal State Budgetary Educational Institution of Higher Professional “Ryazan State Medical University”, Ministry of Healthcare of the Russian Federation
1 shared publication - Natalia Anatolyevna Belykh
Federal State Budgetary Educational Institution of Higher Education “Ryazan State Medical University named after Academician I. P. Pavlov” of the Ministry of Health of the Russian Federation
1 shared publication
Latest Publications
- 17 April 2026
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 36 (2)
The experience of using triple targeted therapy (elexacaftor/ tezacaftor/ivacaftor) in a patient with cystic fibrosis complicated by cystic fibrosis-related diabetes
This article discusses the clinical experience of using triple targeted therapy (elexacaftor/tezacaftor/ivacaftor) in a patient with cystic fibrosis complicated by cystic fibrosis-related diabetes. The description includes details on the diagnostic process, the features of the disease course, and treatment approaches. In addition, the work pays special attention to the use of targeted drugs, as well as the need for an integrated approach to managing the condition of patients with combined disorders. To date, there has been insufficient research on the efficacy of the drug elexacaftor/ tezacaftor/ivacaftor and its effects on patients with comorbid conditions, particularly those suffering from cystic fibrosis-related diabetes. The aim was to highlight modern research on this topic and to assess the effect of triple targeted therapy on the clinical manifestations of the disease. Results. The patient showed significant improvement in the functional state of the lungs, control of blood glucose levels, and overall quality of life. Conclusion. The article summarizes the importance of an individualized approach to therapy that considers both genetic and metabolic aspects of the disease. The conclusion emphasizes the importance of early, timely initiation of treatment to achieve optimal results and improve the prognosis of long-term life in patients with cystic fibrosis and related complications.
- 17 April 2026
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 36 (2)
The experience of using triple targeted therapy (elexacaftor/ tezacaftor/ivacaftor) in a patient with cystic fibrosis complicated by cystic fibrosis-related diabetes
This article discusses the clinical experience of using triple targeted therapy (elexacaftor/tezacaftor/ivacaftor) in a patient with cystic fibrosis complicated by cystic fibrosis-related diabetes. The description includes details on the diagnostic process, the features of the disease course, and treatment approaches. In addition, the work pays special attention to the use of targeted drugs, as well as the need for an integrated approach to managing the condition of patients with combined disorders. To date, there has been insufficient research on the efficacy of the drug elexacaftor/ tezacaftor/ivacaftor and its effects on patients with comorbid conditions, particularly those suffering from cystic fibrosis-related diabetes. The aim was to highlight modern research on this topic and to assess the effect of triple targeted therapy on the clinical manifestations of the disease. Results. The patient showed significant improvement in the functional state of the lungs, control of blood glucose levels, and overall quality of life. Conclusion. The article summarizes the importance of an individualized approach to therapy that considers both genetic and metabolic aspects of the disease. The conclusion emphasizes the importance of early, timely initiation of treatment to achieve optimal results and improve the prognosis of long-term life in patients with cystic fibrosis and related complications.
- Open Access
- 8 August 2025
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 35 (4) , 608-612
Rare lung diseases: Williams – Campbell syndrome
Williams – Campbell syndrome (WCS) is a rare developmental defect characterized by deficiency or complete absence of cartilage mainly in the subsegmental bronchi. Inferiority of the cartilaginous apparatus creates favorable conditions for the development of recurrent lower respiratory tract infection and, as a consequence, the formation of bronchiectasis, which ultimately leads to the appearance and progression of respiratory failure, as well as to a decrease in the quality of life of patients. Insufficient awareness of this disease among doctors leads to later diagnosis, and complex conservative therapy in the absence of specific treatment for WCS entails a positive effect only in the short term.The aim. Demonstration of a clinical case of a rare respiratory disease – WCS in a 35-year-old man.Conclusion. This case illustrates the complexities of diagnosing and treating WCS and highlights the importance of raising awareness among healthcare workers regarding this disease.
- 8 August 2025
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 35 (4) , 608-612
Open AccessRare lung diseases: Williams – Campbell syndrome
Williams – Campbell syndrome (WCS) is a rare developmental defect characterized by deficiency or complete absence of cartilage mainly in the subsegmental bronchi. Inferiority of the cartilaginous apparatus creates favorable conditions for the development of recurrent lower respiratory tract infection and, as a consequence, the formation of bronchiectasis, which ultimately leads to the appearance and progression of respiratory failure, as well as to a decrease in the quality of life of patients. Insufficient awareness of this disease among doctors leads to later diagnosis, and complex conservative therapy in the absence of specific treatment for WCS entails a positive effect only in the short term.The aim. Demonstration of a clinical case of a rare respiratory disease – WCS in a 35-year-old man.Conclusion. This case illustrates the complexities of diagnosing and treating WCS and highlights the importance of raising awareness among healthcare workers regarding this disease.